InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,589.09
(
1.11%
)
Post# of 251707
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Rocky3 post# 113385

Monday, 11/07/2011 10:38:09 PM

Monday, November 07, 2011 10:38:09 PM

Post# of 251707
MNTA’s 3Q11 cash operating expenses excluding R&D revenue (which is essentially reimbursement from NVS) and excluding MNTA’s royalties to MIT* were $17.5M, according to today's CC. This amount is within the $15-18M quarterly range that MNTA has given in prior guidance (#msg-65880685).

*3Q11 royalties to MIT of $2.9M were boosted by the $10M milestone payment MNTA received from NVS for the first anniversary of the Lovenox launch; they will be lower in subsequent quarters.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up